Chronic Airway Therapeutics, a proposed spin-off from Invion
(ASX:IVX) has selected leading Chinese contract research organisation R&G Pharma Studies Co to support the development in China of nadolol as a treatment for chronic obstructive pulmonary disease (COPD).
R&G is one of China’s leading Contract Research Organisations.
CAT selected R&G because of the company’s demonstrated expertise, strong relationships with the China Food and Drug Administration (CFDA), and deep understanding of the similarities and differences with US FDA regulations.
Nadolol, which – unlike existing treatments – can be administered in one single tablet per day, could play an integral role in diminishing the impact of COPD.
Shares in Invion
(ASX:IVX) closed flat at 3.6 cents yesterday.
